“…28,29 Similarly, a thrombosis risk of 1% was reported in patients with congenital hemophilia and inhibitors treated with aPCC. 30 However, risk of thrombosis is higher in patients with AHA treated with bypassing agents. Data from the European AHA (EACH2) registry showed a 2.9% thrombosis risk with recombinant activated factor VII and a 4.8% risk with aPCC.…”